Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ViroPharma Sets Legal Argument Against FDA Decision On Generic Vancocin

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm, which markets vancomycin hydrochloride, says FDA decision on bioequivalence testing violates FOIA and other statutes.

You may also be interested in...



FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.

FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions

46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.

Vancocin Generic In Vivo Testing Waiver Is Not Scientifically Sound, ViroPharma Says

More stringent testing is needed because the product treats two potentially life-threatening diseases, the firm argues in a supplement to its Petition for Stay of Action.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel